With patients in focus, BioArctic develops disease modifying drugs with the aim of stopping or slowing down the progression of Alzheimer’s disease and Parkinson’s disease, based on the company’s antibodies (immunotherapy). BioArctic also develops an innovative potential treatment for Complete Spinal Cord Injury.
BioArctic’s business strategy is to build a research portfolio with a number of innovative projects successively reaching a suitable point for entering into partnerships with global pharma companies. Our research and development work is proceeding in line with this strategy.
All BioArctic’s projects have developed well during the year. The company is collaborating with scientifically leading and financially strong partners in the Alzheimer’s disease and Parkinson’s disease areas, which is a quality mark. BioArctic is developing rapidly with several novel projects in the pipeline and a steady increase in the number of employees and consultants.
Among our five projects for treatment of patients with early stage Alzheimer’s disease, BAN2401 is the most advanced project currently in a Phase 2b clinical trial. The project is run in collaboration with our partner, the Japanese global pharma company Eisai.
Together with research groups at Uppsala University, we are developing a completely new type of PET tracer (positron emission tomography) for imaging of the brain in connection with Alzheimer’s disease by using BioArctic’s antibodies. The project aims at developing an improved diagnostic tool that enables better diagnosis of Alzheimer’s disease, monitoring of progression of the disease and objective measuring of the effect of drug treatment. Our ambition is to create a tool that can be used in research and drug development as well as in commercial applications.
As a result of the research collaboration with AbbVie in Parkinson’s disease we have recruited more employees, gained increased resources and are able to drive the BAN0805 project considerably faster towards clinical studies.
Our Spinal Cord Injury project SC0806 is currently in Phase 1/2 clinical trial in patients with complete Spinal Cord Injury.
So far, the year has been characterized by high expectations and great enthusiasm for the continued positive development of the company. We are looking forward to the important activities ahead of us during the rest of the year.